Journal: Journal of Cancer
Article Title: Mesenchymal stem/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression
doi: 10.7150/jca.37932
Figure Lengend Snippet: Comparison of gp80, gp130, p-STAT3, MMP-9, α-SMA, Ki-67, SOX-2, and vimentin expression and prognosis between NPC patients with IL-6 high CD73 high phenotype and IL-6 low CD73 low phenotype. a. Representative images for the IHC staining of gp80, gp130, p-STAT3, MMP-9, α-SMA, Ki-67, SOX-2, and vimentin in NPC patients with IL-6 high CD73 high phenotype and IL-6 low CD73 low phenotype. b - i. Bar graphic figures showing the relative expression levels, basing on pathological score (PS) of gp80 ( b ), gp130 ( c ), p-STAT3 ( d ), MMP-9 ( e ), α-SMA ( f ), Ki-67 ( g ), SOX-2 ( h ), and Vimentin ( i ) in NPC patients with IL-6 high CD73 high phenotype and IL-6 low CD73 low phenotype. j - k. Comparison of prognosis between NPC patients with IL-6 high CD73 high phenotype and IL-6 low CD73 low phenotype basing on PS ( j ) and TCGA datasets ( k ). *, P < 0.05; **, P < 0.01.
Article Snippet: For immunostaining, primary antibodies against IL-6 (sc-28343, Santa Cruz), CD73 (PA5-29750, Thermo-Fisher), gp80 (IL-6Rα, sc-373708, Santa Cruz), gp130 (sc-655, Santa Cruz), p-STAT3 (sc-8001-R, Santa Cruz), SOX-2 (66411-1-Ig, Proteintech), MMP-9 (sc-393859, Santa Cruz), Ki-67 (27309-1-AP, Proteintech), Vimentin (sc-373717, Santa Cruz) and α-SMA (55135-1-AP, Proteintech) were incubated for 30 min at room temperature, followed by HRP-conjugated secondary detection antibody and diaminobenzidine (DAB).
Techniques: Expressing, Immunohistochemistry